Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Prometheus, Roivant TL1A data look 'highly competitive,' says Piper » 11:05
01/04/23
01/04
11:05
01/04/23
11:05
RXDX

Prometheus

$106.59 /

-0.01 (-0.01%)

, ROIV

Roivant Sciences

$7.25 /

+0.105 (+1.47%)

After Roivant Sciences…

After Roivant Sciences (ROIV) announced results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101, Piper Sandler analyst Yasmeen Rahimi argued that the readout further validates the TL1A mechanism in ulcerative colitis, or UC. Her comparative analysis of Prometheus Biosciences' (RXDX) ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a study results and the TUSCANY induction data lead her to believe Prometheus' PRA023 and Roivant's RVT-3101 have "highly competitive profiles," said Rahimi, who keeps an Overweight rating and $114 price target on Prometheus shares.

ShowHide Related Items >><<
RXDX Prometheus
$106.59 /

-0.01 (-0.01%)

ROIV Roivant Sciences
$7.25 /

+0.105 (+1.47%)

RXDX Prometheus
$106.59 /

-0.01 (-0.01%)

12/08/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/08/22 Credit Suisse
Prometheus price target raised to $142 from $59 at Credit Suisse
12/08/22 Wells Fargo
Prometheus price target raised to $164 from $71 at Wells Fargo
12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
ROIV Roivant Sciences
$7.25 /

+0.105 (+1.47%)

12/28/22 Cantor Fitzgerald
Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
12/27/22 Cantor Fitzgerald
Roivant's upcoming data readouts could move stock higher, says Cantor Fitzgerald
11/15/22 Citi
Roivant Sciences price target raised to $11 from $10 at Citi
10/27/22 JPMorgan
Roivant Sciences initiated with an Overweight at JPMorgan
RXDX Prometheus
$106.59 /

-0.01 (-0.01%)

ROIV Roivant Sciences
$7.25 /

+0.105 (+1.47%)

  • 09
    Dec
  • 08
    Nov
RXDX Prometheus
$106.59 /

-0.01 (-0.01%)

ROIV Roivant Sciences
$7.25 /

+0.105 (+1.47%)

RXDX Prometheus
$106.59 /

-0.01 (-0.01%)

Over a month ago
On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:10
12/09/22
12/09
11:10
12/09/22
11:10
RXDX

Prometheus

$112.19 /

-5.15 (-4.39%)

, REPL

Replimune Group

$24.83 /

+0.68 (+2.82%)

, IBIO

iBio

/

+

, ESPR

Esperion

$5.75 /

-0.43 (-6.96%)

, SNDX

Syndax

$20.82 /

-0.235 (-1.12%)

These names in the…

ShowHide Related Items >><<
SNDX Syndax
$20.82 /

-0.235 (-1.12%)

RXDX Prometheus
$112.19 /

-5.15 (-4.39%)

REPL Replimune Group
$24.83 /

+0.68 (+2.82%)

IBIO iBio
/

+

ESPR Esperion
$5.75 /

-0.43 (-6.96%)

RXDX Prometheus
$112.19 /

-5.15 (-4.39%)

12/08/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/08/22 Credit Suisse
Prometheus price target raised to $142 from $59 at Credit Suisse
12/08/22 Wells Fargo
Prometheus price target raised to $164 from $71 at Wells Fargo
12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
REPL Replimune Group
$24.83 /

+0.68 (+2.82%)

10/14/22 BMO Capital
Replimune Group price target raised to $40 from $30 at BMO Capital
08/16/22 Piper Sandler
Replimune Group price target lowered to $43 from $44 at Piper Sandler
05/24/22 Wedbush
Replimune Group price target lowered to $52 from $59 at Wedbush
05/19/22 Piper Sandler
Replimune Group price target lowered to $44 from $52 at Piper Sandler
IBIO iBio
/

+

10/06/22 Cantor Fitzgerald
iBio downgraded to Neutral from Overweight at Cantor Fitzgerald
ESPR Esperion
$5.75 /

-0.43 (-6.96%)

12/07/22 H.C. Wainwright
H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint
08/03/22 Credit Suisse
Esperion downgraded to Underperform from Neutral at Credit Suisse
05/04/22 JPMorgan
Esperion upgraded to Neutral on achievable estimates at JPMorgan
05/04/22 JPMorgan
Esperion upgraded to Neutral from Underweight at JPMorgan
SNDX Syndax
$20.82 /

-0.235 (-1.12%)

09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
07/28/22 B. Riley
Syndax resumed with a Buy at B. Riley
04/11/22 H.C. Wainwright
Syndax initiated with a Buy at H.C. Wainwright
02/14/22 Goldman Sachs
Syndax initiated with a Buy at Goldman Sachs
SNDX Syndax
$20.82 /

-0.235 (-1.12%)

RXDX Prometheus
$112.19 /

-5.15 (-4.39%)

REPL Replimune Group
$24.83 /

+0.68 (+2.82%)

IBIO iBio
/

+

ESPR Esperion
$5.75 /

-0.43 (-6.96%)

  • 09
    Dec
  • 09
    Dec
  • 07
    Dec
  • 07
    Dec
  • 16
    Dec
SNDX Syndax
$20.82 /

-0.235 (-1.12%)

RXDX Prometheus
$112.19 /

-5.15 (-4.39%)

IBIO iBio
/

+

ESPR Esperion
$5.75 /

-0.43 (-6.96%)

RXDX Prometheus
$112.19 /

-5.15 (-4.39%)

IBIO iBio
/

+

ESPR Esperion
$5.75 /

-0.43 (-6.96%)

Syndicate
Prometheus 4.55M share Secondary priced at $110.00 » 20:04
12/08/22
12/08
20:04
12/08/22
20:04
RXDX

Prometheus

$117.34 /

+21.41 (+22.32%)

The deal size was…

The deal size was increased to $500M from $250M and priced below last closing price of $117.64. Goldman Sachs, SVB Securities, Jefferies and Guggenheim are acting as joint book running managers for the offering.

ShowHide Related Items >><<
RXDX Prometheus
$117.34 /

+21.41 (+22.32%)

RXDX Prometheus
$117.34 /

+21.41 (+22.32%)

12/08/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/08/22 Credit Suisse
Prometheus price target raised to $142 from $59 at Credit Suisse
12/08/22 Wells Fargo
Prometheus price target raised to $164 from $71 at Wells Fargo
12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
RXDX Prometheus
$117.34 /

+21.41 (+22.32%)

  • 09
    Dec
RXDX Prometheus
$117.34 /

+21.41 (+22.32%)

RXDX Prometheus
$117.34 /

+21.41 (+22.32%)

Recommendations
Prometheus price target raised to $111 from $66 at RBC Capital » 09:12
12/08/22
12/08
09:12
12/08/22
09:12
RXDX

Prometheus

$95.85 /

+59.87 (+166.40%)

RBC Capital analyst…

RBC Capital analyst Gregory Renza raised the firm's price target on Prometheus to $111 from $66 and keeps an Outperform rating on the shares. The analyst cites the company's topline data for PRA023 bolstered by commentary and investor feedback, while noting that its conference call offered additional details on the "solid results" which continue to impress with its rapid activity onset, low ADA level and limited impact. Renza adds that his increased price target reflects an increase in the probability of success of the IBD programs and deeper penetrations to reflect a robust clinical profile of PRA023.

ShowHide Related Items >><<
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

12/08/22 Credit Suisse
Prometheus price target raised to $142 from $59 at Credit Suisse
12/08/22 Wells Fargo
Prometheus price target raised to $164 from $71 at Wells Fargo
12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
12/08/22 Oppenheimer
Prometheus price target raised to $125 from $61 at Oppenheimer
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

  • 09
    Dec
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

Recommendations
Prometheus price target raised to $142 from $59 at Credit Suisse » 07:13
12/08/22
12/08
07:13
12/08/22
07:13
RXDX

Prometheus

$95.85 /

+59.87 (+166.40%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth raised the firm's price target on Prometheus to $142 from $59 and keeps an Outperform rating on the shares following ulcerative colitis and Crohn's disease data. The debate is now shifting to the potential size of the class - the analyst believes current market dynamics in IBD remains favorable for a potential best-in-class asset such as PRA023: patients cycle through multiple therapies and there is a substantial pool of biologic-experienced patients that would likely welcome a new MoA. PRA023 has established a highly competitive efficacy profile relative to other biologics in UC, with potentially transformative efficacy in biomarker positive patients if the interim readout results are replicated across registrational studies, offering Prometheus substantial commercial optionality and possibly more favorable pricing/broader access in earlier lines than originally expected, Fauth contends.

ShowHide Related Items >><<
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

12/08/22 Wells Fargo
Prometheus price target raised to $164 from $71 at Wells Fargo
12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
12/08/22 Oppenheimer
Prometheus price target raised to $125 from $61 at Oppenheimer
12/07/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

  • 09
    Dec
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

Recommendations
Prometheus price target raised to $164 from $71 at Wells Fargo » 07:11
12/08/22
12/08
07:11
12/08/22
07:11
RXDX

Prometheus

$95.85 /

+59.87 (+166.40%)

Wells Fargo analyst Derek…

Wells Fargo analyst Derek Archila raised the firm's price target on Prometheus to $164 from $71 and keeps an Overweight rating on the shares after updating his model to reflect the positive Phase 2 ulcerative colitis and Crohn's disease data, and solid trends on its CDx+ approach. Given the data, the analyst thinks Prometheus has meaningful scarcity value for two reasons, namely market leading efficacy in UC all-comers and even better in CDx + pts; while the CDx+ approach will be further validated in the expanded cohort in Q2 2023, Wednesday's data is highly meaningful because it was done prospectively in Prometheus' Phase 2 trials.

ShowHide Related Items >><<
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
12/08/22 Oppenheimer
Prometheus price target raised to $125 from $61 at Oppenheimer
12/07/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/07/22 Guggenheim
Prometheus price target raised to $185 from $75 at Guggenheim
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

  • 09
    Dec
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

Recommendations
Prometheus price target raised to $181 from $74 at BTIG » 06:17
12/08/22
12/08
06:17
12/08/22
06:17
RXDX

Prometheus

$95.85 /

+59.87 (+166.40%)

BTIG analyst Julian…

BTIG analyst Julian Harrison raised the firm's price target on Prometheus to $181 from $74 and keeps a Buy rating on the shares after its phase 2 study results for lead program PRA023 in both ulcerative colitis, UC, and Crohn's disease, CD. The company has set "high watermarks" for the entire inflammatory bowel disease field, with JAK-like efficacy both in UC and CD coupled with a "remarkably clean" safety profile, the analyst tells investors in a research note. PRA023 therapeutic profile is "unprecedented" and likely moves the program to the front of the line in both indications, Harrison adds.

ShowHide Related Items >><<
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

12/08/22 Oppenheimer
Prometheus price target raised to $125 from $61 at Oppenheimer
12/07/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/07/22 Guggenheim
Prometheus price target raised to $185 from $75 at Guggenheim
12/07/22 Piper Sandler
Prometheus price target raised to $114 from $67 at Piper Sandler
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

  • 09
    Dec
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

Recommendations
Prometheus price target raised to $125 from $61 at Oppenheimer » 06:08
12/08/22
12/08
06:08
12/08/22
06:08
RXDX

Prometheus

$95.85 /

+59.87 (+166.40%)

Oppenheimer analyst Jeff…

Oppenheimer analyst Jeff Jones raised the firm's price target on Prometheus to $125 from $61 and keeps an Outperform rating on the shares after the company announced significant Phase 2 wins for lead program PRA023 in both ulcerative colitis and Crohn's disease. Results in UC, with a 25% placebo-adjusted remission rate, exceeded expectations and positions PRA023 as a potential best-in-category contender. This result is further bolstered by the interim CDx readout identifying patients who have potential for a further increased rate of clinical remission, the analyst notes. In CD, results were positive but less dramatic, Jones adds. In both cases, PRA023 demonstrated a clean safety profile.

ShowHide Related Items >><<
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

12/07/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/07/22 Guggenheim
Prometheus price target raised to $185 from $75 at Guggenheim
12/07/22 Piper Sandler
Prometheus price target raised to $114 from $67 at Piper Sandler
12/07/22 Stifel
Stifel 'thoroughly impressed' with Prometheus' data in UC and CD
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

  • 09
    Dec
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

On The Fly
What You Missed On Wall Street On Wednesday » 16:38
12/07/22
12/07
16:38
12/07/22
16:38
CVNA

Carvana

$3.82 /

-2.885 (-43.03%)

, COIN

Coinbase

$41.26 /

-1.08 (-2.55%)

, MC

Moelis

$40.43 /

-0.25 (-0.61%)

, GWH

ESS Inc.

$2.63 /

-0.235 (-8.20%)

, VNCE

Vince Holding

$7.86 /

+0.07 (+0.90%)

, WELL

Welltower

$65.02 /

-3.155 (-4.63%)

, MDB

MongoDB

$178.44 /

+33.7 (+23.28%)

, LOW

Lowe's

$206.94 /

+4.87 (+2.41%)

, TOL

Toll Brothers

$49.51 /

+3.67 (+8.01%)

, CPB

Campbell Soup

$56.16 /

+3.175 (+5.99%)

, SFIX

Stitch Fix

$3.69 /

+0.025 (+0.68%)

, ABNB

Airbnb

$91.52 /

-1.65 (-1.77%)

, EXPE

Expedia

$90.78 /

-6.245 (-6.44%)

, TRIP

TripAdvisor

$17.79 /

-1.22 (-6.42%)

, BKNG

Booking Holdings

$1,955.58 /

-86.485 (-4.24%)

, SEDG

SolarEdge

$310.74 /

+11.65 (+3.90%)

, RXDX

Prometheus

$95.85 /

+59.87 (+166.40%)

, MMAT

Meta Materials

$2.04 /

+0.085 (+4.35%)

, STT

State Street

$80.47 /

+6.175 (+8.31%)

, UNIT

Uniti Group

$6.08 /

-0.975 (-13.83%)

, SNDX

Syndax

$21.87 /

-2.37 (-9.78%)

, AVAV

AeroVironment

$82.39 /

-2.75 (-3.23%)

, BF.A

Brown-Forman

$67.97 /

-5.265 (-7.19%)

, BF.B

Brown-Forman

$68.30 /

-5.375 (-7.30%)

, BFA

Brown-Forman, also tag with BF.A, BF.B

$46.71 /

+ (+0.00%)

, BFB

Brown-Forman, also tag with BF.A, BF.B

/

+

, SWBI

Smith & Wesson Brands

$9.49 /

-2.33 (-19.72%)

, OLLI

Ollie's Bargain Outlet

$47.70 /

-10.05 (-17.40%)

, ASO

Academy Sports

$56.89 /

+7.555 (+15.32%)

Get caught up quickly on…

ShowHide Related Items >><<
WELL Welltower
$65.02 /

-3.155 (-4.63%)

VNCE Vince Holding
$7.86 /

+0.07 (+0.90%)

UNIT Uniti Group
$6.08 /

-0.975 (-13.83%)

TRIP TripAdvisor
$17.79 /

-1.22 (-6.42%)

TOL Toll Brothers
$49.51 /

+3.67 (+8.01%)

SWBI Smith & Wesson Brands
$9.49 /

-2.33 (-19.72%)

STT State Street
$80.47 /

+6.175 (+8.31%)

SNDX Syndax
$21.87 /

-2.37 (-9.78%)

SFIX Stitch Fix
$3.69 /

+0.025 (+0.68%)

SEDG SolarEdge
$310.74 /

+11.65 (+3.90%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

OLLI Ollie's Bargain Outlet
$47.70 /

-10.05 (-17.40%)

MMAT Meta Materials
$2.04 /

+0.085 (+4.35%)

MDB MongoDB
$178.44 /

+33.7 (+23.28%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

GWH ESS Inc.
$2.63 /

-0.235 (-8.20%)

EXPE Expedia
$90.78 /

-6.245 (-6.44%)

CVNA Carvana
$3.82 /

-2.885 (-43.03%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

COIN Coinbase
$41.26 /

-1.08 (-2.55%)

BKNG Booking Holdings
$1,955.58 /

-86.485 (-4.24%)

BFA Brown-Forman, also tag with BF.A, BF.B
$46.71 /

+ (+0.00%)

BF.B Brown-Forman
$68.30 /

-5.375 (-7.30%)

BF.A Brown-Forman
$67.97 /

-5.265 (-7.19%)

AVAV AeroVironment
$82.39 /

-2.75 (-3.23%)

ASO Academy Sports
$56.89 /

+7.555 (+15.32%)

ABNB Airbnb
$91.52 /

-1.65 (-1.77%)

CVNA Carvana
$3.82 /

-2.885 (-43.03%)

12/07/22 William Blair
Carvana downgraded to Market Perform from Outperform at William Blair
12/07/22 Wedbush
Carvana downgraded to Underperform from Neutral at Wedbush
11/30/22 BofA
BofA downgrades Carvana to Neutral on liquidity concerns
11/30/22 BofA
Carvana downgraded to Neutral from Buy at BofA
COIN Coinbase
$41.26 /

-1.08 (-2.55%)

12/05/22 Atlantic Equities
Coinbase price target lowered to $46 from $67 at Atlantic Equities
12/02/22 Piper Sandler
Piper calls for 'more aggressive headcount reduction' at Coinbase
11/22/22 Needham
Coinbase price target lowered to $73 from $89 at Needham
11/22/22 Barclays
Coinbase price target lowered to $44 from $55 at Barclays
MC Moelis
$40.43 /

-0.25 (-0.61%)

11/03/22 Keefe Bruyette
Moelis downgraded to Underperform from Market Perform at Keefe Bruyette
09/23/22 UBS
Moelis downgraded to Sell from Neutral at UBS
07/18/22 Morgan Stanley
Moelis downgraded to Underweight from Equal Weight at Morgan Stanley
07/11/22 Wolfe Research
Moelis downgraded to Underperform from Peer Perform at Wolfe Research
GWH ESS Inc.
$2.63 /

-0.235 (-8.20%)

10/27/22 EF Hutton
ESS Inc. initiated with a Buy at EF Hutton
07/13/22 Canaccord
ESS Inc. assumed with a Hold at Canaccord
06/29/22 Chardan
ESS Inc. initiated with a Neutral at Chardan
03/30/22 Deutsche Bank
ESS Inc. initiated with a Hold at Deutsche Bank
VNCE Vince Holding
$7.86 /

+0.07 (+0.90%)

WELL Welltower
$65.02 /

-3.155 (-4.63%)

12/08/22 Morgan Stanley
Welltower Integra JV risk not a 'thesis changer,' says Morgan Stanley
12/02/22 Mizuho
Welltower price target lowered to $91 from $93 at Mizuho
11/21/22 Evercore ISI
Welltower downgraded to In Line from Outperform at Evercore ISI
11/01/22 Morgan Stanley
Welltower price target lowered to $72 from $90 at Morgan Stanley
MDB MongoDB
$178.44 /

+33.7 (+23.28%)

12/07/22 Stifel
MongoDB consumption commentary positive for Datadog, says Stifel
12/07/22 Credit Suisse
MongoDB price target lowered to $305 from $400 at Credit Suisse
12/07/22 Oppenheimer
MongoDB price target lowered to $320 from $375 at Oppenheimer
12/07/22 Needham
MongoDB price target lowered to $225 from $330 at Needham
LOW Lowe's
$206.94 /

+4.87 (+2.41%)

12/08/22 Wedbush
Lowe's price target raised to $200 from $190 at Wedbush
12/07/22 Goldman Sachs
Lowe's price target raised to $246 from $241 at Goldman Sachs
12/07/22 Baird
Baird remains 'opportunistic buyer' of Lowe's after investor meeting
12/06/22 Bernstein
Lowe's initiated with a Market Perform at Bernstein
TOL Toll Brothers
$49.51 /

+3.67 (+8.01%)

12/08/22 Barclays
Toll Brothers price target raised to $50 from $47 at Barclays
11/22/22 JPMorgan
Toll Brothers upgraded to Overweight from Neutral at JPMorgan
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
10/21/22 Raymond James
Toll Brothers downgraded to Market Perform from Outperform at Raymond James
CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

12/08/22 Piper Sandler
Campbell Soup price target raised to $55 from $46 at Piper Sandler
12/08/22 Deutsche Bank
Campbell Soup price target raised to $53 from $50 at Deutsche Bank
11/15/22 Exane BNP Paribas
Campbell Soup initiated with an Underperform at Exane BNP Paribas
09/13/22 UBS
Campbell Soup's top-line guidance may be hard to achieve, says UBS
SFIX Stitch Fix
$3.69 /

+0.025 (+0.68%)

12/07/22 Evercore ISI
Stitch Fix price target lowered to $6 from $7 at Evercore ISI
12/07/22 Barclays
Stitch Fix price target lowered to $4 from $5 at Barclays
09/22/22 Barclays
Stitch Fix price target lowered to $5 from $7 at Barclays
09/21/22 Truist
Stitch Fix price target lowered to $6 from $8 at Truist
ABNB Airbnb
$91.52 /

-1.65 (-1.77%)

12/06/22 Morgan Stanley
Airbnb downgraded to Underweight at Morgan Stanley on 'supply bear case'
12/06/22 Morgan Stanley
Airbnb downgraded to Underweight from Equal Weight at Morgan Stanley
11/22/22 Barclays
Airbnb price target raised to $103 from $101 at Barclays
11/22/22 Baird
Airbnb downgraded to Neutral from Outperform at Baird
EXPE Expedia
$90.78 /

-6.245 (-6.44%)

12/07/22 Wolfe Research
Expedia downgraded to Underperform from Peer Perform at Wolfe Research
11/22/22 Barclays
Expedia price target raised to $125 from $124 at Barclays
11/08/22 Citi
Expedia price target lowered to $102 from $118 at Citi
11/06/22 Barclays
Expedia price target lowered to $124 from $161 at Barclays
TRIP TripAdvisor
$17.79 /

-1.22 (-6.42%)

12/07/22 Wolfe Research
TripAdvisor downgraded to Underperform from Peer Perform at Wolfe Research
11/25/22 DA Davidson
TripAdvisor price target lowered to $30 from $33 at DA Davidson
11/09/22 Wells Fargo
TripAdvisor price target lowered to $22 from $30 at Wells Fargo
11/09/22 Mizuho
TripAdvisor price target lowered to $22 from $26 at Mizuho
BKNG Booking Holdings
$1,955.58 /

-86.485 (-4.24%)

12/07/22 Wolfe Research
Booking Holdings downgraded to Peer Perform from Outperform at Wolfe Research
11/22/22 Barclays
Booking Holdings price target raised to $2,430 from $2,370 at Barclays
11/07/22 Susquehanna
Booking Holdings price target lowered to $2650 from $2800 at Susquehanna
11/03/22 Deutsche Bank
Booking Holdings price target raised to $2,370 from $2.280 at Deutsche Bank
SEDG SolarEdge
$310.74 /

+11.65 (+3.90%)

12/07/22 BofA
SolarEdge upgraded to Buy from Neutral at BofA
12/05/22 Cowen
SolarEdge price target raised to $360 from $309 at Cowen
12/02/22 RBC Capital
RBC Capital 'not surprised' by Commerce Department's finding on solar companies
12/01/22 Roth MKM
U.S. to announce 'affirmative' finding in solar trade case, says Roth Capital
RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

12/08/22 Credit Suisse
Prometheus price target raised to $142 from $59 at Credit Suisse
12/08/22 Wells Fargo
Prometheus price target raised to $164 from $71 at Wells Fargo
12/08/22 BTIG
Prometheus price target raised to $181 from $74 at BTIG
12/08/22 Oppenheimer
Prometheus price target raised to $125 from $61 at Oppenheimer
MMAT Meta Materials
$2.04 /

+0.085 (+4.35%)

STT State Street
$80.47 /

+6.175 (+8.31%)

12/06/22 Morgan Stanley
State Street downgraded to Equal Weight from Overweight at Morgan Stanley
12/01/22 Wells Fargo
State Street price target raised to $84 from $71 at Wells Fargo
12/01/22 Citi
State Street price target raised to $85 from $81 at Citi
11/15/22 Deutsche Bank
State Street price target raised to $77 from $66 at Deutsche Bank
UNIT Uniti Group
$6.08 /

-0.975 (-13.83%)

11/13/22 Citi
Uniti Group price target lowered to $9 from $12 at Citi
SNDX Syndax
$21.87 /

-2.37 (-9.78%)

09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
07/28/22 B. Riley
Syndax resumed with a Buy at B. Riley
04/11/22 H.C. Wainwright
Syndax initiated with a Buy at H.C. Wainwright
02/14/22 Goldman Sachs
Syndax initiated with a Buy at Goldman Sachs
AVAV AeroVironment
$82.39 /

-2.75 (-3.23%)

12/07/22 Canaccord
AeroVironment price target raised to $106 from $105 at Canaccord
11/18/22 Canaccord
AeroVironment price target raised to $105 from $100 at Canaccord
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
11/10/22 Raymond James
AeroVironment upgraded to Outperform from Market Perform at Raymond James
BF.A Brown-Forman
$67.97 /

-5.265 (-7.19%)

10/10/22 Wedbush
Brown-Forman initiated with a Neutral at Wedbush
10/10/22 Wedbush
Brown-Forman initiated with a Neutral at Wedbush
BF.B Brown-Forman
$68.30 /

-5.375 (-7.30%)

12/08/22 Deutsche Bank
Brown-Forman price target lowered to $72 from $73 at Deutsche Bank
09/28/22 Truist
Brown-Forman reinstated with a Buy at Truist
BFA Brown-Forman, also tag with BF.A, BF.B
$46.71 /

+ (+0.00%)

BFB Brown-Forman, also tag with BF.A, BF.B
/

+

SWBI Smith & Wesson Brands
$9.49 /

-2.33 (-19.72%)

12/07/22 Lake Street
Smith & Wesson Brands price target lowered to $13.50 from $22 at Lake Street
12/07/22 Craig-Hallum
Smith & Wesson Brands price target lowered to $12 from $17 at Craig-Hallum
09/09/22 Lake Street
Smith & Wesson Brands price target lowered to $22 from $26 at Lake Street
OLLI Ollie's Bargain Outlet
$47.70 /

-10.05 (-17.40%)

12/08/22 Wells Fargo
Ollie's Bargain Outlet price target lowered to $60 from $70 at Wells Fargo
12/08/22 Citi
Ollie's Bargain Outlet price target lowered to $52 from $55 at Citi
12/08/22 Gordon Haskett
Ollie's Bargain Outlet downgraded to Accumulate from Buy at Gordon Haskett
10/24/22 Gordon Haskett
Ollie's Bargain Outlet initiated with a Buy at Gordon Haskett
ASO Academy Sports
$56.89 /

+7.555 (+15.32%)

12/08/22 Loop Capital
Academy Sports price target raised to $65 from $60 at Loop Capital
12/08/22 Wells Fargo
Academy Sports price target raised to $70 from $56 at Wells Fargo
11/28/22 Wedbush
Black Friday winners Include Best Buy, losers include Pets, says Wedbush
09/09/22 Loop Capital
Academy Sports initiated with a Buy at Loop Capital
WELL Welltower
$65.02 /

-3.155 (-4.63%)

VNCE Vince Holding
$7.86 /

+0.07 (+0.90%)

UNIT Uniti Group
$6.08 /

-0.975 (-13.83%)

TRIP TripAdvisor
$17.79 /

-1.22 (-6.42%)

TOL Toll Brothers
$49.51 /

+3.67 (+8.01%)

SWBI Smith & Wesson Brands
$9.49 /

-2.33 (-19.72%)

STT State Street
$80.47 /

+6.175 (+8.31%)

SNDX Syndax
$21.87 /

-2.37 (-9.78%)

SFIX Stitch Fix
$3.69 /

+0.025 (+0.68%)

SEDG SolarEdge
$310.74 /

+11.65 (+3.90%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

OLLI Ollie's Bargain Outlet
$47.70 /

-10.05 (-17.40%)

MDB MongoDB
$178.44 /

+33.7 (+23.28%)

MC Moelis
$40.43 /

-0.25 (-0.61%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

GWH ESS Inc.
$2.63 /

-0.235 (-8.20%)

EXPE Expedia
$90.78 /

-6.245 (-6.44%)

CVNA Carvana
$3.82 /

-2.885 (-43.03%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

COIN Coinbase
$41.26 /

-1.08 (-2.55%)

BKNG Booking Holdings
$1,955.58 /

-86.485 (-4.24%)

BFA Brown-Forman, also tag with BF.A, BF.B
$46.71 /

+ (+0.00%)

BF.A Brown-Forman
$67.97 /

-5.265 (-7.19%)

AVAV AeroVironment
$82.39 /

-2.75 (-3.23%)

ASO Academy Sports
$56.89 /

+7.555 (+15.32%)

ABNB Airbnb
$91.52 /

-1.65 (-1.77%)

  • 07
    Dec
  • 22
    Apr
  • 18
    Mar
  • 16
    Dec
WELL Welltower
$65.02 /

-3.155 (-4.63%)

VNCE Vince Holding
$7.86 /

+0.07 (+0.90%)

TOL Toll Brothers
$49.51 /

+3.67 (+8.01%)

SWBI Smith & Wesson Brands
$9.49 /

-2.33 (-19.72%)

STT State Street
$80.47 /

+6.175 (+8.31%)

SFIX Stitch Fix
$3.69 /

+0.025 (+0.68%)

SEDG SolarEdge
$310.74 /

+11.65 (+3.90%)

MC Moelis
$40.43 /

-0.25 (-0.61%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

GWH ESS Inc.
$2.63 /

-0.235 (-8.20%)

EXPE Expedia
$90.78 /

-6.245 (-6.44%)

CVNA Carvana
$3.82 /

-2.885 (-43.03%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

COIN Coinbase
$41.26 /

-1.08 (-2.55%)

BKNG Booking Holdings
$1,955.58 /

-86.485 (-4.24%)

BF.A Brown-Forman
$67.97 /

-5.265 (-7.19%)

ASO Academy Sports
$56.89 /

+7.555 (+15.32%)

ABNB Airbnb
$91.52 /

-1.65 (-1.77%)

WELL Welltower
$65.02 /

-3.155 (-4.63%)

VNCE Vince Holding
$7.86 /

+0.07 (+0.90%)

TRIP TripAdvisor
$17.79 /

-1.22 (-6.42%)

TOL Toll Brothers
$49.51 /

+3.67 (+8.01%)

STT State Street
$80.47 /

+6.175 (+8.31%)

SNDX Syndax
$21.87 /

-2.37 (-9.78%)

SFIX Stitch Fix
$3.69 /

+0.025 (+0.68%)

SEDG SolarEdge
$310.74 /

+11.65 (+3.90%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

OLLI Ollie's Bargain Outlet
$47.70 /

-10.05 (-17.40%)

MMAT Meta Materials
$2.04 /

+0.085 (+4.35%)

MC Moelis
$40.43 /

-0.25 (-0.61%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

GWH ESS Inc.
$2.63 /

-0.235 (-8.20%)

EXPE Expedia
$90.78 /

-6.245 (-6.44%)

CVNA Carvana
$3.82 /

-2.885 (-43.03%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

COIN Coinbase
$41.26 /

-1.08 (-2.55%)

BKNG Booking Holdings
$1,955.58 /

-86.485 (-4.24%)

AVAV AeroVironment
$82.39 /

-2.75 (-3.23%)

ASO Academy Sports
$56.89 /

+7.555 (+15.32%)

WELL Welltower
$65.02 /

-3.155 (-4.63%)

UNIT Uniti Group
$6.08 /

-0.975 (-13.83%)

TRIP TripAdvisor
$17.79 /

-1.22 (-6.42%)

TOL Toll Brothers
$49.51 /

+3.67 (+8.01%)

SWBI Smith & Wesson Brands
$9.49 /

-2.33 (-19.72%)

STT State Street
$80.47 /

+6.175 (+8.31%)

SFIX Stitch Fix
$3.69 /

+0.025 (+0.68%)

SEDG SolarEdge
$310.74 /

+11.65 (+3.90%)

RXDX Prometheus
$95.85 /

+59.87 (+166.40%)

MMAT Meta Materials
$2.04 /

+0.085 (+4.35%)

MDB MongoDB
$178.44 /

+33.7 (+23.28%)

LOW Lowe's
$206.94 /

+4.87 (+2.41%)

EXPE Expedia
$90.78 /

-6.245 (-6.44%)

CVNA Carvana
$3.82 /

-2.885 (-43.03%)

CPB Campbell Soup
$56.16 /

+3.175 (+5.99%)

COIN Coinbase
$41.26 /

-1.08 (-2.55%)

ASO Academy Sports
$56.89 /

+7.555 (+15.32%)

ABNB Airbnb
$91.52 /

-1.65 (-1.77%)

Syndicate
Prometheus announces $250M common stock offering » 16:08
12/07/22
12/07
16:08
12/07/22
16:08
RXDX

Prometheus

$96.97 /

+60.99 (+169.51%)

Prometheus Biosciences…

Prometheus Biosciences announced that it intends to offer and sell, subject to market and other conditions, $250M of shares of its common stock in an underwritten public offering. Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments to fund the development of PRA023, PRA052 and its other research and development programs, and for working capital and general corporate purposes. Goldman Sachs & Co., SVB Securities, Jefferies, and Guggenheim Securities are acting as joint bookrunning managers for the offering.

ShowHide Related Items >><<
RXDX Prometheus
$96.97 /

+60.99 (+169.51%)

RXDX Prometheus
$96.97 /

+60.99 (+169.51%)

12/07/22 RBC Capital
Prometheus price target raised to $111 from $66 at RBC Capital
12/07/22 Guggenheim
Prometheus price target raised to $185 from $75 at Guggenheim
12/07/22 Piper Sandler
Prometheus price target raised to $114 from $67 at Piper Sandler
12/07/22 Stifel
Stifel 'thoroughly impressed' with Prometheus' data in UC and CD
RXDX Prometheus
$96.97 /

+60.99 (+169.51%)

RXDX Prometheus
$96.97 /

+60.99 (+169.51%)

RXDX Prometheus
$96.97 /

+60.99 (+169.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.